# Orchestra BioMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/orchestra-biomed

- Industry: Biotechnology
- Headquarters: New Hope, US
- Website: www.orchestrabiomed.com
- Total disclosed funding: $144M
- Latest round: Series D (Jun 1, 2022)
- Investors on record: 6

## About

Orchestra BioMed, Inc. is a company focused on developing innovative therapeutic products aimed at addressing unmet medical needs in hypertension and atherosclerotic artery disease.Founded in 2017, Orchestra BioMed, Inc. is based in New Hope, US. The company specializes in creating advanced medical solutions. It has completed a MERGER that raised USD 20.00 mn, which is part of the total amount raised of USD 110.00 mn, with notable investors including Health Sciences Acquisitions Corporation 2, Medtronic plc, and RTW Investments. The company has executed 8 deals since its inception. David Hochman serves as CEO, succeeding prior leadership in the company.Orchestra BioMed specializes in the development of innovative therapeutic product candidates that target significant unmet medical needs in the treatment of hypertension and atherosclerotic artery disease. Their core offerings include BackBeat CNT™, an investigational bioelectronic treatment designed to provide immediate and sustained reductions in blood pressure while modulating the autonomic nervous system. Additionally, the company is advancing Virtue SAB, a novel drug/device combination that delivers an extended-release formulation of sirolimus during balloon angioplasty procedures, eliminating the need for balloon coating or permanent implants. These products are in late-stage development and aim to serve healthcare providers and patients in global markets where hypertension and arterial diseases are prevalent, particularly in regions with high incidences of cardiovascular conditions.Orchestra BioMed's revenue model is primarily based on strategic partnerships with leading medical device companies, enabling the commercialization of their innovative products. The company engages in risk-reward sharing arrangements that align their interests with those of their partners, facilitating the development and distribution of their flagship products, BackBeat CNT™ and Virtue SAB. Transactions typically involve collaborative agreements that may include milestone payments, royalties on sales, and shared clinical development costs. These financial structures support the efficient progression of their product candidates through various stages of development and into the market, ensuring that they can address critical health challenges effectively.Orchestra BioMed, Inc. plans to expand its product offerings and geographic reach. Future products are currently under design with a focus on enhancing therapeutic options for hypertension and arterial diseases. The company aims to penetrate additional markets with high cardiovascular condition rates by leveraging its recent MERGER funding of USD 20.00 mn, which will support further product development and market entry initiatives. Recently, Orchestra BioMed raised venture funding from new investor Kinled Holding to bolster its ongoing projects.

## Funding rounds

- Series D, Jun 1, 2022, $110M — Medtronic, RTW Investments, SternAegis Ventures, Terumo, Perceptive Advisors
- Series B, Jun 28, 2019, $24M — RTW Investments, SternAegis Ventures, Terumo, Perceptive Advisors, Soleus Capital
- Series B, Apr 15, 2019, $9.9M — SternAegis Ventures

## Investors

- SternAegis Ventures (https://capitalatlas.ai/funds/sternaegis-ventures) — Series B, Series D
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B, Series D
- Terumo — Series B, Series D
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B, Series D
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series B
- Medtronic — Series D